Control Bionics (ASX:CBL) Cash per Share: A$0.01 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Control Bionics Cash per Share?

Control Bionics ASX:CBL -3.03% Cash per Share is A$0.01 as of Dec. 2025. The stock has 4 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Control Bionics's Cash per Share for the quarter that ended in Dec. 2025 was A$0.01.

Control Bionics  (ASX:CBL) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Control Bionics Cash per Share Related Terms

Control Bionics Cash per Share Historical Data

* Premium members only.

The historical data trend for Control Bionics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics Cash per Share Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash per Share
Get a 7-Day Free Trial 0.13 0.05 0.01 0.01 0.00

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.00 0.00 0.01

Control Bionics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Control Bionics's Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=0.595/299.74
=0.00

Control Bionics's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3.057/411.96
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of A$0.01 mean?
Control Bionics (ASX:CBL) has a Cash per Share of A$0.01 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Control Bionics and its competitors.
Is Control Bionics' Cash per Share too high?
Control Bionics' current Cash per Share is A$0.01.
How does Control Bionics' Cash per Share compare to ABT and SYK?
Control Bionics' Cash per Share of A$0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Medical Devices & Instruments company?
A good Cash per Share depends on the Medical Devices & Instruments industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Control Bionics and its competitors. Control Bionics's current Cash per Share is A$0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.06 — trading 113.3% above its estimated fair value. The current Cash per Share is A$0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Cash per Share is A$0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.